Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 148 participants.

Also called NCT07667517

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 148 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07667517
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07667517. Randomized; triple masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2027-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease
Condition
Albuminuria
Condition
Type 2 Diabetes Mellitus (T2DM)
Condition
Chronic Kidney Diseases
Intervention (Drug)
Finerenone (BAY 94-8862)
Intervention (Drug)
Placebo
Lead sponsor
First Affiliated Hospital of Zhejiang University (class: other)

Record details

Record id
cardio:ct-nct07667517
Content hash
5f17928fa172a5503493d9ff73743b759071d1cc9a19cd43b7274ebb88e24b10